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SUMMARY
Exogenous agents correlated with hepatocellular carcinoma (HCC) have been identified and well characterized. These agents,
including the different viruses that cause chronic hepatitis and cirrhosis, can lead to regenerative nodules and dysplastic nodules/
adenomatous hyperplasia. These conditions associated with several molecular alterations of hepatocyte ultimately culminate in
hepatocellular carcinoma. Recently, there has been a great progress in the identification of somatic and germinative mutations that
may be correlated with the development of HCC, justifying a review on the subject. Hence, the factors involved in the process of
hepatic carcinogenesis, such as infection by the hepatitis B and C viruses, with a special focus in the molecular alterations described
in recent years are discussed herein, pointing out areas potentially relevant for clinical development.
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INTRODUCTION
The carcinogenesis is a complex event, involving alterations in several
genes and, depending also of external factors, such as infection by
hepatitis B or C and chronic alcohol intake, can lead to a pre-neoplastic
lesion, like the low and high grade displastic nodule / adenomatous
hyperplasia105. Subsequently, this lesion can progress to early cancer
and finally, culminate with advanced hepatocellular carcinoma (HCC)4.
The knowledge about the development and progression to HCC have
increased in later years with the increasing using of several molecular
biology techniques71,80. Thus, one of the most frequent molecular events
in cancer is an aberrant gene expression. This can be due to both genetic
alterations - like point mutations or deletions in segments of genes - or
to epigenetic modifications that modulate the gene function, like gene
methylation, without changing the DNA sequence but altering the
resulting protein. The activation of oncogenes and inactivation of tumor
suppressor genes (TSG) have an important role in the mechanisms of
cancer development. These genes can induce malignant transformation
when inappropriately expressed as a result of mutation, deletion,
amplification or rearrangement. Overexpression of oncogenes leads to
constitutive activity of key regulatory molecules that are normally
modulated during the cell cycle. In the case of HCC, the activation of
oncogenes has been seen with a low frequency, leading some authors to
suggest a secondary role of this genetic event. On the other hand, reports
of inactivation of TSG are increasing seen in the process of hepatic
carcinogenesis. Thus, the advances of molecular genetics of HCC as
summarized in Fig. 1 and Table 1, already justify a review on the theme.
Fig. 1 - Molecular model for hepatocarcinogenesis (see the text). Figure adapted from CHAN,
et al., 1999.6
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Furthermore, the progress generated by the publication of the first
draft of the human genome, the start up of several projects post-genome
sequencing to identify human genes and the knowledge acquired with
molecular biology will soon make an impact in the routine of the
physicians management of several diseases. We will, thus, try to discuss
several factors involved in the process of hepatic carcinogenesis, such
as infection by the hepatitis B and C viruses, the related molecular
alterations recently discovered and their relevance for clinical
management.
HEPATITIS B VIRUS: Hepatitis B virus (HBV) has a circular DNA
genome, with about 3.2 kb, which can originate an acute and chronic
necroinflammatory response from the liver85. In fact, HBV is not directly
cytopathic to the hepatocyte, and it is believed that the hepatic disease is
due to an immunologic response to the viral antigens expressed by the
infected hepatocytes. The virus is composed of several forms of proteins:
large envelope protein, transactivating protein that contains the HBV X,
core-pre core proteins and viral polymerase. The HBV infection during
the adult life is often subclinical, and most of the adult patients with
acute hepatitis B recovers completely and eliminate the virus15. About
5% of the patients infected during adult life, however, will have persistent
infection and will develop chronic hepatic disease. In contrast, more
than 90% of the patients with neonatal transmission of the HBV develop
chronic disease. Vertical transmission of HBV is common in areas of
Africa and Asia with high demographic density, and because of that
hundreds of thousands of people are chronically infected5,79. Many of
these individuals will develop chronic hepatic diseases, and even cirrhosis
and HCC still in young ages. In Taiwan there are about 433 cases of
HCC per 100,000 HBV infected male, compared to 5 cases per 100,000
persons without infection by HBV2. In Japan, where neonatal
transmission of HBV is rare, the risk of developing HCC in patients
with diagnosis of chronic infection by HBV is 7 fold higher the in non-
infected individuals97.
HCC-induced by HBV is likely the result of a variety of
mechanisms71. (I) The viral integration into the host genome, that would
lead to an alteration in genes regulating cell cycle; (II) Chronic hepatitis
or hepatic cirrhosis could lead to a hipermutagenic status affecting cell
cycle genes by somatic mutation and/or epigenetic alteration, promoting
deregulated proliferation; (III) Chronic liver inflammation could lead to
a mutagenesis prone environment; (IV) The viral transactivating protein
HBV X, after host genome integration, could cause deregulation of genes
involved in the cell cycle, such as p53 and p21Waf1, among others.
All of these mechanisms have been investigated in patients infected
with HBV and in several animal models for studying hepatitis. One of
the first used models was the woodchuck88. Captive woodchucks infected
at birth with woodchuck hepatitis virus (WHV), a DNA-virus very similar
to the HBV, developed HCC after 17 to 36 months of persistent infection
in 97% of the cases; WHV infection occurring during adult life carries a
far lower risk of HCC development. This pattern of infection is somewhat
analogous to the HCC incidence within HBV infection in humans.
Integrated WHV genomes are found in most cases of HCC in woodchucks
infected at birth or while young, as it is the case for human patients with
chronic HBV infection. Integration of WHV causes deletions,
translocations and inversions of host chromosomes. However, no
predominant transforming oncogenes and no characteristic chromosomal
abnormality have been identified. Integration events leading to the direct
activation of oncogenes and inactivation of tumor-suppressor genes,
therefore, seem to be rare and random in both woodchucks and humans,
and only in a few cases can be correlated with unordered cellular
proliferation. Alterations in the expression of the insulin growth factor
type II detected in the pre-neoplastic lesion in the liver of woodchucks
infected with WHV are potentially important because the gene of IGF-
II is deleted in several human HCC samples118. Nonetheless the integration
of HBV can lead to rearrangements of chromosome 11p, and this may
also account for the deletions observed in this chromosome in HCC
patients. However, differences between this animal model and cancer in
humans have also been observed; the activation of mutation in the
oncogenes n-myc and c-myc is frequently found in woodchucks67, but
these alterations have not been found in HCC associated with hepatitis.
Recently several models of infection by HBV have been studied in
transgenic mice8. These transgenic mice have been constructed containing
only HBV-derived regulatory sequences that express all of the viral gene
products and replicate the virus in the hepatocyte. Therefore, they are
considered to be excellent models for dissecting the human disease. One
potential problem with this methodology is that the expression of HBV
genes and the process of viral replication are not per se cytotoxic for the
hepatocytes. On the other hand, the abnormal expression of two products
of viral genome, the large envelope protein and the protein HVB X can
lead to HCC development (Fig. 2). Transgenic mice expressing large
Table 1
Molecular alterations in hepatocellular carcinoma (Modified from OZTURK80)
Gene Mutation(%) Other alterations References
p53 20 – 70 Interaction with HBx gene, aflatoxin 14,22,32,70
Cyclin D 11 Amplification 73
p16Ink4 0 – 50 Hypermethylation, decreased expression 7,39
p21Waf1/Cip1 0 Decreased expression 29,37
Rb 15 Homozygous deletion 57,120
Beta-catenin 16 – 26 Increased expression 64
M6P/IGF2R 18-33 Homozygous deletion 17,84
E-cadherin Methylation 42,43
COX-2 Increased expression 53,95
hTERT Increased telomerase activity in about 80% of HCC 55,101
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amounts of the HBV large envelope protein show severe hepatitis, and
the degree of hepatocellular injury is directly proportional to the amount
of HBsAg maintained in the endoplasmic reticulum. Prolonged storage
of the long subviral particles in the endoplasmic reticulum in large
amounts can lead the hepatocytes to die spontaneously. This chronic
hepatocellular necrosis causes a secondary inflammatory and regenerative
response, which leads to HCC in all transgenic mouse strains
overexpressing the large envelope protein8,9. Hepatocellular turnover in
these mice, relative to nontransgenic controls, is increased 100-fold for
at least a year before the onset of HCC36. Moreover, there is a dramatic
increase in the oxidative damage of the hepatocellular genomic DNA. It
is reasonable to assume that these events could lead to and are
fundamental for the HCC formation in these animals, and can serve as
reference in the human hepatocarcinogenesis.
A high level of expression of the HBV X protein in transgenic mice
results in almost ubiquitous HCC in some mouse strains49,54. The
transgenic mouse strains that develop HCC upon overexpression of the
HBV X protein have a CD-1 genetic background. They are naturally
susceptible to HCC and as such have been used extensively to study
hepatic carcinogenesis. The transgenic mouse strains that express the X
protein in a genetic background other than CD-1 do not develop HCC.
These findings suggest that the X protein may function as a cofactor in
promoting HCC, besides host genetic susceptibility. The mechanism by
which these mice develop HCC is not fully understood22,48,108. It has been
shown that the HBV X protein interacts with the wild-type human p53
protein and inhibits its sequence-specific DNA binding and
transcriptional activity in vitro. Furthermore, the HBV X protein can
transcriptionally activate several cellular genes in vitro, including c-myc
and c-jun, which are associated with growth control, what could also be
transforming.
HEPATITIS C VIRUS: Hepatitis C virus (HCV) is a RNA virus,
of approximately 10 kb, belonging to the Flaviridae family10,85 and is
acquired mainly by parenteral exposure5; it has been considered the main
agent causing chronic hepatitis, cirrhosis and HCC15,66,96,103. Due to the
great sequence heterogeneity of the viral genome, HCV is classified
into various subtypes, with different epidemiological characteristics98,99.
The viral replication, from a RNA strand into a new RNA strand, does
not involve a DNA synthesis step and, thus, no viral integration in the
host genome. Some scientists propose a cytopathic action of HCV, due
to the structural analogy with several known cytopathic virus, such as
flavivirus and pestivirus. However, this has been vigorously contested
by those who believe in the existence of “asymptomatic carrier of HCV”.
The HCV genome codes for a polyprotein of 3,010 to 3,033
aminoacids11. This polyprotein is processed into at least 10 proteins, of
which four are structural (core, E1, E2 and p7) and 6 non-structural
(NS2, NS3, NS4A, NS4B, NS5A and NS5B). KATO et al., working at
Omata’s lab, showed that the HCV core and NS4B proteins45,46 work as
an induction agent in the activation of intracellular signal, specially in
the system NF-kB, AP1 and SRE, contributing for cellular proliferation
and production of inflammatory cytokines, potentially relevant in the
formation of HCC. MORIYA et al. accepted that transgenic mice for the
HCV core gene developed sequentially: hepatic steatosis, adenomas and
hepatocarcinomas66. Altogether, these results imply that HCV can have
an important role in hepatocarcinogenesis.
p53: The p53 gene is one of the most important tumor suppressor
genes, being altered in more than half of all different kinds of tumor and
HCC is not an exception to this rule86,106. This gene has characteristics of
tumor suppressor in its wild-type form and can function as a dominant
oncogene when mutated. Usually, the altered protein of a tumor
suppressor gene is due to the loss of heterozigosity of one allele and
another mutation in the remaining one, according to the “two-hits theory”
proposed by KNUDSON Jr. et al.52. Exceptionally, p53 is a transcription
factor that requires alteration of only one of its alleles to have its function
altered, since the mutant protein prevails and inhibits the function of the
wild type protein112. The 20 kb-gene is located in the short arm of
chromosome 17 and contains 11 exons (protein-coding nucleotides),
and 10 introns (non-coding nucleotides). The messenger RNA codes for
a protein of 393 amino acids, which is expressed at low levels in all
different tissues of the body. The p53 gene product is a phosphoprotein
of 53 kDa involved in several functions to maintain the cellular
homeostasis. Cell cycle and apoptosis are two key determinants of the
cell fate controlled by p53. Cell cycle arrest at the “checkpoints” in G1
and G2 (Fig. 3) allows the process of DNA repair and prevent mutation
or other genetic alterations to be transmitted to the next cellular
Fig. 2 - Transgenic mice and hepatocellular carcinoma (see the text).
Fig. 3 - Cell cycle and control of G1-G0 check point (see the text).

NITA, M.E.; ALVES, V.A.F.; CARRILHO, F.J.; ONO-NITA, S.K.; MELLO, E.S. & GAMA-RODRIGUES, J.J. - Molecular aspects of hepatic carcinogenesis. Rev. Inst. Med. trop. S. Paulo,
44(1):39-48, 2002.
generation. When DNA damage is severe with no possible repair, the
cell can undergo a programmed death, named apoptosis, in which specific
genes are activated and lead the cell to commit suicide. Upon DNA
damage, the p53 gene is activated and acts in vital regulatory functions
through, for instance, p21Waf1/Cip1 - arresting the cell cycle (see cell
cycle below) - and Bcl-2 and Bax proteins leading to apoptosis. This is
why p53 was called the “guardian of the genome”59, explaining the high
frequency of alterations in this gene in many different kinds of cancer.
In liver cancer, p53 is closely associated to aflatoxins - which are toxins
produced by the fungus Aspergillus flavus and related species, that grow
in food like peanuts, corn and rice when stored in inadequate conditions
of high temperature and humidity, creating the perfect environment for
the fungus reproduction. The HCC found in patients from areas with
high exposure to aflatoxin, like China, Senegal and other African
countries, has been associated with a specific mutation in the p53 gene35,81.
About 20 to 75% of the HCC-patients from these regions have a p53
mutation, which in most of the cases is a G to T transversion in the third
nucleotide of codon 249 - resulting in substitution of arginine by
serine14,70,115. This mutation has been found in individuals with intense
exposure to aflatoxin B1, but with an apparently normal liver, suggesting
that this is an early genetic event in the process of hepatocarcinogenesis.
On the other hand, this mutation has not been found in regions with
high incidence of HCC and HBV; thus it is likely that the hepatitis B
virus is not associated with this particular type of p53 mutation. In areas
with low levels of aflatoxin, like Japan and some European countries,
the frequency of this type of p53 alteration is much lower, about 10 to
20% depending on the area30,33,44,113,115.
CELL CYCLE: Cancer cells are characterized by unlimited and
unordered growth due to disequilibrium between cell proliferation and
death. The intimate relation between cancer and some genes that control
cell cycle has been elucidated by molecular biology74,76,107. Cell cycle is
divided into four phases: G1 phase (gap1), S phase (DNA synthesis),
G2 phase (gap2) and mitotic phase (Fig. 3). The progression through
each phase is controlled by intracellular signals, that either negatively
control the cycle, arresting the cell cycle, or positively control the cycle,
allowing the advance into the next phase41,92. The G1 phase is well defined
and frequently associated with carcinogenesis; at this point, the genes
that positively control the cell cycle to proceed into the next phase code
for cyclins and cyclin dependent kinases (CDK). The main substrate of
cyclin and CDK is the retinoblastoma gene product (Rb); the wild-type
form of the Rb gene inhibits the development of tumor. Phosphorylation
of Rb by the cyclin/CDK complex allows progression of the cell cycle
by freeing the E2F family of proteins. The inhibition of this machinery
occurs through a class of small proteins called CDK inhibitors (CKI),
such as p16INK4, p21Waf1/cip1 and p27Kip1, and their alteration have
been associated with different types of cancers. Besides these, other genes,
such as p53 and TGF-beta (transforming growth factor–beta), are
involved in the G1 phase of the cell cycle by regulating the CKI.
Any alteration in any level of this pathway can break the regulatory
machinery, resulting in unordered and continuous cellular growth–two
paradigms of a cancer cell. That is why these genes are being intensely
researched and the study of the alteration of the genes p16INK4,
p21Waf1/cip1 and p27Kip1, Cyclin D1, p53, Rb, and TGF-beta receptor
II are leading to a better understanding of the carcinogenesis process in
several different neoplasias74,106,107, among them, the hepatocellular
carcinoma38,72.
Cyclin D1 is one of the cyclins that when associated with CDK
phosphorilates the Rb protein, allowing cellular proliferation. The
chromosomal location of the Cyclin D1 gene is 11q13 and its protein
expression is altered in HCC. Neoplastic hepatocytes have a 3 times
increased expression of Cyclin D1 when compared with normal
hepatocyte; this alteration was also confirmed at DNA level, in which
amplification of the Cyclin D1–gene was found mainly in advanced
cases73,121. Since this alteration may be associated with a more aggressive
behavior of the tumors, it is believed that the amplification and
overexpression of Cyclin D1 can deregulate cell proliferation.
The product of the gene p16INK4 was initially identified as a protein
of 16 kDa that inhibits the Cyclin/CDK complex, not allowing
phosphorylation of Rb and, consequently, stopping the cell cycle. The
gene p16INK4 is located in the region 9p21 and is also called MTS1
(multiple tumor suppressor 1), because it is involved in multiple types
of cancer, being melanoma the best studied. This gene has several ways
of being inactivated, and some of them are different from the classical
p53 and Rb genes that are inactivated by point mutations; the p16INK4
gene is inactivated by homozygous deletion in mesothelioma and bladder
cancer considering that it is inactivated by point mutation in melanomas,
esophageal and biliary tract cancer. Besides these genetic alterations,
p16INK4 can be inactivated by an epigenetic modification, such as
hypermethylation, like was observed in lung-carcinoma small cell and
colon cancer. The product of the p16INK4 gene is altered in about 34%
of hepatocellular carcinomas39 and in about 22% of early cases of HCC.
These results suggest that p16INK4 can be involved in the early phases
of the hepatocellular carcinogenesis. CHAUBERT et al.7,50 also suggest
that the inactivation of this gene occur mainly by hypermethylation in
48% of the HCC cases, and their data were confirmed by WONG et al.114.
The p21Waf1/cip1 gene is one of the main substrates for p53 and is
the link between p53 and cell cycle. Furthermore, p21 is considered to
be an universal inhibitor of the cyclin/CDK complex, thus also inhibiting
the cell cycle. Several experiments have suggested that the p21Waf1/
cip1 could suppress tumoral growth, being then a potential tumor
suppressor gene. However, the p21Waf1/cip1 gene is seldom mutated in
most of the cancers, leading the researchers to look for possible alterations
at the expression level29. HUI et al. found that this gene has low levels of
mRNA in almost 40% of HCC; they also found a correlation between
this low level of expression and mutation in p5337. Taking all in
consideration, it is possible that the p21Waf1/cip1 gene contributes to
the process of hepatocarcinogenesis93.
Finally, the p27Kip1 gene, located at the 12p13 and identified due
to its ability to interact with TGF-beta, is another negative regulator of
cell cycle and is structurally related to p21Waf1/cip1. Similarly to the
latter, the p27Kip1 gene rarely presents a mutation. However, alteration
in its expression level has been correlated with prognosis in breast and
colon cancer. HUI et al.40, studying this gene at the protein level, showed
that p27Kip1 expression is decreased in more than half of primary liver
cancer. Yet, FIORENTINO et al.24 observed that patients with high
expression level of p27Kip1 survived longer than those with low level
of expression. Therefore, this gene may be used as a prognostic marker.
The retinoblastoma gene (Rb) is, together with p53, a classical
example of tumor suppressor gene. It is located at chromosome 13q14
and when phosphorylated allows cell proliferation. The loss of the region
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where this gene is located is frequently observed in about 30% of patients
with HCC, and it was associated with loss of protein function. Probably,
such gene inactivation is involved in the process of hepatocarcino-
genesis120. More recently, it was demonstrated that the E2F1 family of
genes, that complex with Rb, is associated with adenomas and HCC in
animal models of hepatocarcinogenesis13.
In summary, drawing all these studies together, it is clear that,
although those alterations are not necessarily correlated between
themselves, HCC patients have at least one of them present in their
tumors. Thus, loss of cell cycle regulation in HCC is frequently found,
and can be involved in the hepatic carcinogenesis, since it could lead to
an unordered growth of the hepatocyte. The elucidation of the machinery
governing the cell cycle may allow novel preventive and therapeutic
approaches aiming to correct these alterations.
APOPTOSIS: Apoptosis, or programmed cell death, is a biologic
process essential to several physiologic and pathologic conditions47,74,78.
The number of cells in a living organism depends basically on the balance
between cellular proliferation and apoptosis, and breaking the
homeostasis between these two processes can contribute to the appearance
of a hepatic disease. High rate of apoptosis seems to be involved in viral
hepatitis, cholestatic diseases, such as primary biliary cirrhosis, and
hepatic disease induced by alcohol82. On the other hand, low rate of
apoptosis in hepatocytes allows survival of cells that otherwise would
die, leading to neoplastic transformation, due to clonal expansion of
cells with molecular abnormalities. Alternatively, there would be an
increase of apoptosis rate in the hepatocellular carcinoma and in the pre-
neoplastic lesions, but not enough to compensate for the increased
proliferation rate that features in cancer tissue31. Furthermore, inhibition
of apoptosis is one of the main mechanisms of acquiring treatment
resistance, such as chemoresistance, that characterize solid tumors; thus
approaches that induce apoptosis can be a way to overcome resistance
to solid-tumors treatment18,19,91. Among the genes controlling apoptosis,
the emerging Bcl-2 family of apoptosis regulators56 was the first gene of
this family to be identified, and thereafter a series of novel genes were
isolated. These genes are now divided in two groups: those that block
apoptosis, such as Bcl-2 and Bcl-XL; and those that induce apoptosis,
such as Bax, Bak and Bcl-XS. In vitro studies have shown that Bcl-2 or
Bcl-XL overexpression, as well as Bax deficiency, can confer resistance
to antineoplastic drugs25,63. Conversely, the overexpression of Bcl-XS or
Bax can sensitize neoplastic cells to radiotherapy or chemotherapy89.
The Bcl-2 gene product was immunohistochemically found in HCC,
but not in pre-neoplastic lesions such as dysplasia122. This finding suggests
that overexpressed Bcl-2 could be detected by immunohistochemistry
and explored as a marker for neoplasia. There are, however, some recent
reports describing the Bcl-XL gene, and not the Bcl-2, as the predominant
gene in HCC116. Experimental work61 showed that hepatoblastoma cell
lines have an increased sensitivity to the chemotherapy drugs when the
expression of the Bcl-XL gene is reduced, or the opposite when the
gene is fully expressed28. Similar results have been obtained by
experimental work with colorectal cancer cell lines75,77. These works
suggest that Bcl-XL can be a target for genetic therapy allowing the
overcome of chemoresistance in digestive cancers. Another important
protein that is involved in the interaction of the tumor with the immune
system is the Fas (Apo-1, CD95), a member of the family of the nerve
growth factor/tumoral necrosis factor that mediates apoptosis in response
to specific antibodies after ligation with Fas-L. In normal liver, Fas is
weakly expressed in the hepatocyte membrane and cell of the biliary
duct, while Fas-L is not expressed. In chronic hepatitis, Fas-L is expressed
in areas of high interface activity, being variable in the case of HCC.
WNT SIGNALLING PATHWAY (APC/AXIN/BETA–
CATENIN/TCF): The Wnt signalling pathway plays a critical and
evolutionarily conserved role on regulating the cell fate in different phases
of organogenesis and regulation of cell-cell interaction (Fig. 4). The
genes involved in the Wnt signaling pathway are also involved in several
types of cancer, including the HCC12. At the cell membrane, the Wnt
signal links to the family of Frizzled receptors, a transmembrane cellular
receptor. The signal triggered by Wnt goes down through several
cytoplasmic molecules, such as APC, axin and GSK3beta, and stabilizes
the beta–catenin protein65. This protein is then accumulated and enters
the nucleus, where it forms a complex with Tcf/Lef (also known as
lymphocyte enhancer-binding factor). Together, they function as a
transcription factor activating the genes involved in several cellular
functions, such as c-myc34. When Wnt signal is absent, the signal
transduction pathway is off because beta–catenin is rapidly destroyed
and can not enter the nucleus. Inactivation of APC or axin by mutations
can result in permanent activation of the Wnt signaling pathway and
accumulation of beta–catenin in the cytoplasm. Mutation in the CTNNB1
gene, that codes for the beta–catenin64, or in the APC gene (Adenomatous
Polyposis Coli responsible for adenomatous familiar polyposis – FAP)
have been reported in several types of cancer65. The hepatic cancer,
however, shows a higher occurrence of abnormal distribution and
accumulation of beta-catenin than it would be expected by the rate of
mutation in the gene CTNNB1, raising the hypothesis that beta-catenin
accumulation would be due to other reasons12. In the case of colorectal
cancer the innapropriate activation of Tcf/Lef by beta-catenin can occur
by means of APC inactivation, an important tumor suppressor gene
involved in the colorectal carcinogenesis. Alterations, nevertheless, of
APC are very rare in the case of HCC. SATO et al., working at the
Nakamura’s lab, studied HCC derived cell lines and 100 primary liver
tumors, and uncovered that the axin gene is mutated in HCC90. Axin has
features of a tumor suppressor, and they reported that both alleles are
inactivated in some tumors, by mutation or loss of heterozigosity (LOH),
in accordance with the Knudson hypothesis51. Thus, it is possible that
axin is a new tumor suppressor gene. Functional analysis of this gene
Fig. 4 - Wnt/APC/Axin/Beta catenin/Tcf signalling pathway (see the text). Figure adapted
from PEIFER et al., 200083.
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showed that all mutations detected in that study would yield a truncated
protein missing the binding site for beta-catenin. Moreover, they reported
that mutation on any of these genes, CTNNB1 (beta-catenin) ou Axin,
leads to an increased interaction with TCF/LEF in the nucleus64,90. They
also have shown that genetic therapy with transfection of the wild-type
axin gene in liver or colon cancer cells can induce these cells to apoptosis
in background where the beta-catenin was accumulated either by mutation
on APC or CTNNB1 or axin. Taking together, these experiments not
only give further insights to the understanding of hepatocarcinogenesis,
but also indicate a possible way for treatment of both liver cancer and
colon cancer.
ALLELOTYPE STUDIES – LOSS OF HETEROZIGOSITY:
Loss of heterozigosity (LOH) studies, in certain chromossomal regions,
is a frequently employed strategy for the detection of alleles alteration
in the human genome23,110. A LOH indicates a situation where there is
loss of a second allele on one chromossome that had already lost the
other one by a germinative alteration (two-hits theory by KNUDSON)51.
Such alteration is preferably detected in a malignant tumor as compared
with the heterozygous state in the normal tissue. For such study, the
chromossomes can be conveniently divided into a few hundreds loci
whose loss of integrity (LOH) can be indirectly pointed out by specific
markers. The loci showing LOH suggest that the genes residing in these
regions have been preferentially removed during the cancer development,
and thus, can be considered candidates for tumor suppressor genes (TSG).
Table 2 depicts some chromosome regions in which LOH were described
as the likely candidates to TSG near this region and the occurrence of
this fact in early stages of HCC.
Chromosome 1p allelic loss was studied in 104 cases of HCC and
was detected in 38% of the early tumors (less than 2 cm) and in 33% of
the well differentiated tumors, indicating that it might be an early event
associated with HCC development58,104. The gene M6P/IGFR2 (mannose
6-phosphate/insulin-like growth factor-II receptor) reside on chromosome
6q, where was observed LOH in cancer tissues16 and in pre-neoplastic
lesions of the liver117. Moreover, it was described in HCC a mutation in
the other allele in about 18 to 32% of the cases17,84. The M6P/IGFR-2
gene interacts with IGFII, and activates the growth inhibitor TGF-beta,
regulating cellular proliferation. Another chromosome described by
researchers at the University of Tokyo as being altered in about 1/4 of
the early cases of the studied HCC is 8p57. In this region DLC1 (Deleted
in Liver Cancer) was isolated, and it is a gene with low expression level
in HCC, a potentially novel tumor suppressor gene. More recently,
another gene with decreased expression in hepatic tumors was reported
in this region and called LPTS – for liver-related putative tumor
suppressor60. Functional studies, using gene transfection techniques,
showed that LPTS is able to control the growth of cancer cells in vitro,
suggesting that this gene may inhibit the growth of hepatocytes. The
region of chromosome 13q is also important because it harbors the genes
Rb and BRCA23,57. The 13q region showed allelic imbalance in about
15% of the early HCC and 36% of the cases of well differentiated HCC57.
Loss of chromosome 16q appears to be one of the most common genetic
defects in HCC119. One of the candidates to be the target is the E-cadherin
gene – located on 16q22.1. Although no mutations or gross structural
alterations of this gene have been reported in HCC, loss of E-cadherin
expression has been observed in this type of cancer94. Recently, de novo
methylation of the 5’CpG island of the E-cadherin gene has been found
in 46% of liver tissue showing chronic hepatitis or cirrhosis and in 67%
of the HCC analyzed42. Such epigenetic change correlated significantly
with reduced E-cadherin expression. It is suspected that the inactivation
of this gene by deletion or hypermethylation may play an important role
in the development of HCC43. In the region of p53, 17p, it was also
observed LOH in 17% of the early tumors and 35% of the well-
differentiated tumors, being, thus, this gene a possible target for genetic
therapy in the near future. For this reason, the wild-type p53 gene is
transfected to the cancer cell in the hope that the correction of this
abnormality leads to an effective treatment of HCC. It is important to
note that the discrepancy between high LOH rates in the 17p region and
the low frequency of p53 deletion in some reports may indicate the
presence of another tumor suppressor gene in this region.
GENETIC ALTERATION OF THE ONCOGENES RAS AND
MYC: The oncogenes ras and myc are reported to be involved in the
process of pancreas and colo-rectal carcinogenesis. Frequently, these
oncogenes are targets of mutations, amplifications and deletions that
can lead to an overexpression of their proteins, triggering a process of
hyper activation of regulatory molecules involved in important cellular
functions, such as cell cycle and apoptosis. Alteration of the ras genes
has been described in animal models of hepatocarcinogenesis26, but this
result is yet to be confirmed in human hepatocellular carcinoma88,100.
Most authors, therefore, believe that they do not play an important role
in the liver cancer development.
Table 2
Chromosomal location, frequency of LOH, the gene most likely to be in this region and if it is reported to be an early event or not
Chromosome Frequency of LOH1 Associated gene Early event
1p 32%58,104 p73 Yes in 38%58
4q 40 to 83%3,119 - Yes in 17%58
6q 35 to 80%3,17 IGF-II/M6p-receptor17 Yes16,117
8p 50 to 60%3,60 DLC-1? LPTS?60 Yes in 25%57
10q 25%27 PTEN/MMAC1 No
13q 25 to 50%3,68 Rb or BRCA-2 Yes in 15%57
16p 40%3,90 Axin No
16q 36 to 70%3,27,119 E-cadherin No
17p 36 to 54%3,27,58,68 p53 Yes in 17%58 and 50%68
1- LOH, loss of heterozigosity
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COX2: Cyclooxygenase (Cox) is the key enzyme in the conversion
of arachidonic acid to prostaglandin and has been the focus of a series of
research in the field of inflammatory diseases and carcinogenesis21. Two
isoforms of this enzyme were recently identified: the COX-1 variant is
constitutively expressed in most of the tissues, while its isoform, COX-
2, is inducible by a variety of physiologic stimuli, including cytokines,
growth factors, and tumor promoters. This inducible isoform was found
to be upregulated in several human cancers, including colon cancer,
gastric cancer, and squamous cell carcinoma20,87. A significant reduction
in mortality from colorectal cancer has been reported for individuals
taking nonsteroidal anti-inflammatory drugs (NSAIDs), attributed to the
inhibition of the isoform COX-2 in the cancer cells. Recently, this COX-
2 variant was also described to present an increased expression in
hepatocellular carcinoma, mainly in those small and well differentiated
tumors53. This finding led these authors to suggest that this change might
be an early event in the development of HCC. Similar results were
published by other groups1,95, raising the possibility that COX inhibitors
may have a therapeutic or preventive role in liver cancer similarly to
what has been seen for colorectal tumors1.
TELOMERASE: At the end of a chromosome there are long 5’
DNA repeats called telomeres. This structure consists of DNA and
proteins, and, in eukaryotic cells, the telomeres DNA sequence cannot
be completely copied during the replication mechanism. Therefore,
telomeres undergo progressively shortening within each mitotic cycle
as part of the normal ageing process. The length of telomeres seems to
be determined by the enzymatic activity of telomerase. Upon an increased
activity of this enzyme, a ribonucloprotein that is necessary to maintain
the cancer cell tend to immortality, the telomere has its length increased
and the cell extend its potential to continuous replication or even become
resistant to the death62. The reactivation of telomerase activity and the
change in the length of the telomeres have been described in most cases
of HCC55,69,101,102, and at early phases of HCC development55. For this
reason, monitoring telomerase activity has been assessed as a potential
molecular marker for early cancer diagnosis, not only in HCC but in
several other types of cancer. However, in a small percentage of the
cases the altered telomerase activity has also been observed in normal
cells. Although, these authors101 explain these changes in normal cells as
a consequence of the presence of inflammatory cells, the confirmation
of this finding in other series may jeopardize the utility of telomerase in
the process of differential diagnosis of hepatic lesions.
CONCLUSION
Compared with other solid tumors, such as the digestive tract
tumors109,111, the process of molecular carcinogenesis of HCC is still not
clear. There are several genes possibly related to hepatocarcinogenesis
but confirmation of these preliminary studies is yet to be provided. Figure
1 shows a model proposed for the process of hepatocarcinogenesis. There
are about 30,000 to 50,000 genes in each human cell, and it is necessary
to identify those that are involved in the process of hepatocarcinogenesis.
We believe that the disclosure of such genes and their function will make
it feasible to create new tools for diagnosis, follow up and treatment of
HCC patients. We hope that with this review of molecular alteration of
HCC can, by reviewing the current knowledge, stimulate new lines of
research and open up the possibility of daily use in clinical setting of the
genetic alteration described until now.
RESUMO
Aspectos moleculares da carcinogênese hepática
Agentes exógenos correlacionados com o carcinoma hepatocelular
(HCC) têm sido identificados e bem caracterizados. Esses agentes, entre
os quais se incluem os diferentes vírus que causam hepatite e cirrose
hepática, podem provocar o aparecimento de nódulos regenerativos e
nódulos displásicos/hiperplasia adenomatosa. Essas condições associadas
com diversas alterações moleculares do hepatócito podem culminar com
o aparecimento do HCC. Recentemente, grandes progressos têm ocorrido
na identificação de mutações somáticas ou germinativas que estariam
correlacionadas com o desenvolvimento do HCC, justificando ampla
revisão do tema. Procuramos discutir nesta revisão os fatores envolvidos
no processo de carcinogênese hepática, tal como a infecção pelos vírus
das hepatites B e C, com ênfase nas alterações moleculares descritas nos
últimos anos, assinalando áreas em que potenciais avanços na abordagem
clínica poderão surgir em futuro próximo.
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